Vor Biopharma (NASDAQ:VOR) Shares Up 7.2% on Analyst Upgrade

Vor Biopharma Inc. (NASDAQ:VOR) shot up 7.2% during mid-day trading on Thursday after Citigroup upgraded the stock to a strong-buy rating. The company traded as high as $20.02 and last traded at $20.0950. 122,578 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 1,057,865 shares. The stock had previously closed at $18.75.

Other analysts have also issued research reports about the company. Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Wedbush raised their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Vor Biopharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Investors Weigh In On Vor Biopharma

Large investors have recently modified their holdings of the stock. Cannon Global Investment Management LLC bought a new position in shares of Vor Biopharma during the 1st quarter worth approximately $209,000. Sei Investments Co. bought a new stake in Vor Biopharma in the first quarter valued at $245,000. Independent Financial Group LLC bought a new stake in Vor Biopharma in the first quarter valued at $249,000. Wellington Management Group LLP acquired a new position in Vor Biopharma during the second quarter worth $499,000. Finally, Irenic Capital Management LP acquired a new position in Vor Biopharma during the first quarter worth $583,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Stock Performance

The firm has a 50 day simple moving average of $21.57 and a 200-day simple moving average of $18.37.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Equities analysts anticipate that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.